NCT03163381

Apatinib Second Line Treatment for Advanced Osteosarcoma and Soft Tissue Sarcomas ,Openting ,Single Center, One-armed Clinical Study.

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 40 (estimated)
• Sponsor: Henan Cancer Hospital · Other Government
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

Apatinib second line treatment for Advanced osteosarcoma and soft tissue sarcomas ,openting ,single center, one-armed clinical study.

Detailed description

The treatment of bone and soft tissue sarcomas are usually surgery and chemotherapy,advanced cases cannot be removed through surgical method for multiple metastasis,advanced cases Most advanced cases with chemotherapy is given priority to, but the effect is not ideal.Apatinib main through inhibit VEGFR to give play to Anti-angiogenesis effect to treatment of malignant tumor.

Conditions

• Osteosarcoma, Advanced

Interventions

Type	Name	Description
DRUG	Apatinib	Apatinib 500mg,po,qd,medicine to disease progression.

Timeline

• Start date: 2017-04-11
• Primary completion: 2017-10-11
• Completion: 2019-04-11
• First posted: 2017-05-23
• Last updated: 2017-05-23

Locations

1 site across 1 country: China